Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
Kimberly-Clark Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $31.3B | |
|---|---|---|
| Revenue (ttm) | 16.6B | |
| Net income (ttm) | 2B | |
| EPS (ttm) | $5.86 | |
| Shares out | 332.6M | |
| P/E (trailing) | 18.5x | |
| P/E (forward) | 13.1x | |
| Dividend | $5.12 (4.73%) | |
| Volume | 2,561,172 | |
| Beta | 0.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $19.44B | $20.18B | $17.15B | $16.81B | $16.45B | -4.1% |
| Gross profit | $5.99B | $6.22B | $6.27B | $6.29B | $5.92B | -0.3% |
| Operating income | $2.56B | $2.68B | $1.93B | $2.70B | $2.35B | -2.1% |
| Net income | $1.81B | $1.93B | $1.76B | $2.55B | $2.02B | +2.7% |
| EPS (diluted) | $5.35 | $5.72 | $5.21 | $7.55 | $6.07 | +3.2% |
| EBITDA | $3.25B | $3.38B | $2.34B | $3.98B | $3.11B | -1.1% |
| R&D | $269.0M | $292.0M | $303.0M | $328.0M | $326.0M | +4.9% |
| SG&A | $3.40B | $3.58B | $3.88B | $4.31B | $3.53B | +0.9% |
Recent company headlines from major financial publishers.
In the base case, Kimberly-Clark delivers steady turnaround execution, with revenue expanding 0.96% in FY2026 ($16,605M) and 2.65% in FY2027 ($17,045M). Operating margins widen through FY2030 as the 2024 Transformation Initiative offsets input inflation and normalizes supply chain operations, supporting Fair value at $121.76.
In the bull case, premium innovation tiering accelerates volume-plus-mix expansion across Huggies, Kleenex, and Kotex, while the resolution of false China quality allegations drives a sharper recovery in International Personal Care. Gross productivity savings exceed baseline cost inflation, expanding operating margins toward peer benchmarks and generating robust free cash flow to accelerate debt reduction and shareholder returns, supporting valuation toward $163.21.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 5.7% | $135 | $141 | $147 | $154 | $163 |
| 6.2% | $124 | $128 | $133 | $138 | $145 |
| 6.7% | $115 | $118 | $122 | $126 | $131 |
| 7.2% | $107 | $110 | $113 | $116 | $120 |
| 7.7% | $101 | $103 | $105 | $108 | $111 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |